Ascletis Pharma reports positive Phase II results for diabetes drug ASC30
1 report, 1 independent
Updated Oct 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ascletis Pharma announced positive topline results from a U.S. Phase II study evaluating ASC30, an oral GLP-1 receptor agonist, for Type 2 Diabetes Mellitus (T2D). The drug met its primary endpoint, achieving significant HbA1c reduction (1.7% to 1.6% at 40 mg and 60 mg, and 1.7% at 80 mg). Secondary results showed weight reduction and favorable safety and tolerability, with zero study discontinuations due to gastrointestinal adverse events.
From manilatimes.net
Why it matters
The positive results for ASC30, which is being developed for T2D as a second indication after obesity, suggest potential for new treatments in the diabetes market.
From manilatimes.net
Who's involved
- Hong KongLocation where Ascletis Pharma announced the positive clinical results.